Influence of Frailty on Cardiovascular Events and Mortality in Patients With COPD.

ConditionRole of Frailty in COPD

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age40+

SponsorAzienda Ospedaliero-Universitaria di Modena

About this trial

Observational study on the influence of frailty on cardiovascular risk in COPD.

Eligibility criteria

Qualifiers

Patients with age ≥18 years, with diagnosis of COPD of at least 1 year, in stable condition, without acute exacerbation in the last 30 days and/or all-cause hospitalisation in the last 3 months

Smoking history of ≥ 10 pack/years

Diagnosis of COPD according to GOLD guidelines (www.goldcopd.org)

Individuals able to provide their written informed consent.

Disqualifiers

Concurrent diagnosis of interstitial lung disease

Presence of restrictive pattern on spirometry

No history of smoking habit

Individuals not able to provide their written informed consent.

Trial design

Treatments tested in this trial

Assessment of cardiovascular events, cardiovascular mortality, all-cause mortality, and mortality due to COPD at 12 and 24 months

Treatment groups

300 Participants

are divided into 1 treatment group

Sponsors and collaborators

Azienda Ospedaliero-Universitaria di Modena

Lead sponsor

Campus Bio-Medico Universitario di Roma-Medicina Interna - Servizio di Pneumologia

Collaborator

Ospedale Sant'Andrea - Azienda Sanitaria Locale di Vercelli-Reparto di Pneumologia

Collaborator

Hospitals - Aneurin Bevan University Heath Board (Wales) - United Kingdom

Collaborator

Source ClinicalTrials.gov